|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.73 USD | +1.48% |
|
-0.72% | +55.74% |
| Dec. 05 | Royalty Pharma Insider Sold Shares Worth $4,375,008, According to a Recent SEC Filing | MT |
| Dec. 04 | Denali Therapeutics and Royalty Pharma announce $275 million royalty funding agreement | RE |
| Capitalization | 16.97B 14.59B 13.67B 12.74B 23.53B 1,528B 25.6B 160B 61.73B 722B 63.71B 62.35B 2,638B | P/E ratio 2025 * |
13.8x | P/E ratio 2026 * | 12.1x |
|---|---|---|---|---|---|
| Enterprise value | 24.33B 20.91B 19.59B 18.26B 33.73B 2,190B 36.69B 229B 88.48B 1,034B 91.31B 89.36B 3,781B | EV / Sales 2025 * |
7.67x | EV / Sales 2026 * | 7.81x |
| Free-Float |
66.08% | Yield 2025 * |
2.21% | Yield 2026 * | 2.33% |
Last Transcript: Royalty Pharma plc
| 1 day | +1.48% | ||
| 1 week | -0.72% | ||
| Current month | -0.72% | ||
| 1 month | +3.03% | ||
| 3 months | +10.15% | ||
| 6 months | +17.61% | ||
| Current year | +55.74% |
| 1 week | 38.97 |  | 40.21 |
| 1 month | 37.31 | | 40.5 |
| Current year | 25.4 | | 41.24 |
| 1 year | 24.05 | | 41.24 |
| 3 years | 24.05 | | 42.87 |
| 5 years | 24.05 | | 53.23 |
| 10 years | 24.05 | | 56.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 61 | 1995-12-31 |
Terrance Coyne
DFI | Director of Finance/CFO | 43 | 2009-12-31 |
Sara Klymkowsky
CTO | Chief Tech/Sci/R&D Officer | - | 2011-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Pablo Legorreta
CHM | Chairman | 61 | 2020-03-31 |
Errol de Souza
BRD | Director/Board Member | 71 | 2020-05-31 |
Gregory Norden
BRD | Director/Board Member | 67 | 2020-02-10 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 12.98% | 303 M€ | -21.21% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.48% | -0.72% | +53.34% | -5.70% | 16.97B | |
| -0.41% | -6.06% | +22.21% | +171.61% | 905B | |
| -0.27% | -2.41% | +35.24% | +13.98% | 487B | |
| -1.15% | -0.71% | +28.32% | +36.69% | 400B | |
| +1.66% | +2.33% | +22.94% | +4.37% | 330B | |
| 0.00% | -1.79% | +26.97% | +20.08% | 281B | |
| +0.17% | +2.90% | +20.03% | +25.77% | 255B | |
| -1.16% | -4.87% | -3.27% | -9.42% | 248B | |
| -2.29% | -3.75% | -61.31% | -32.54% | 214B | |
| -3.02% | -4.51% | +21.03% | +15.44% | 178B | |
| Average | -0.12% | -2.07% | +16.55% | +24.03% | 331.35B | |
| Weighted average by Cap. | -0.02% | -2.78% | +17.96% | +55.44% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.17B 2.73B 2.55B 2.38B 4.4B 285B 4.78B 29.86B 11.53B 135B 11.9B 11.65B 493B | 3.26B 2.8B 2.63B 2.45B 4.52B 293B 4.92B 30.71B 11.86B 139B 12.24B 11.98B 507B |
| Net income | 1.23B 1.05B 987M 920M 1.7B 110B 1.85B 11.55B 4.46B 52.11B 4.6B 4.5B 191B | 1.63B 1.4B 1.31B 1.22B 2.26B 147B 2.46B 15.35B 5.93B 69.26B 6.12B 5.99B 253B |
| Net Debt | 7.35B 6.32B 5.92B 5.52B 10.2B 662B 11.09B 69.27B 26.75B 313B 27.6B 27.01B 1,143B | 8.49B 7.3B 6.84B 6.37B 11.77B 764B 12.8B 79.98B 30.88B 361B 31.87B 31.19B 1,320B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 39.73 $ | +1.48% | 10,237,502 |
| 25-12-04 | 39.15 $ | -1.14% | 4,401,554 |
| 25-12-03 | 39.60 $ | +0.18% | 3,109,755 |
| 25-12-02 | 39.53 $ | -0.93% | 4,751,714 |
| 25-12-01 | 39.90 $ | -0.30% | 3,905,185 |
Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RPRX Stock
Select your edition
All financial news and data tailored to specific country editions
